UK secures 60 million doses of Novavax’s COVID-19 Vaccine Candidate (NVX-CoV2373)

In addition, a Phase III double-blind, placebo-controlled RCT in approximately 9,000 UK adults is expected to begin later this year. The trial will assess the ability of NVX-CoV2373 to protect against symptomatic COVID-19 disease as well as evaluate antibody and T-cell responses.


Biospace Inc.